Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal conjugate vaccine (serogroups A, C, W-135, and Y)
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **meningococcal conjugate vaccine (serogroups A, C, W-135, and Y)** is an injectable subunit vaccine designed for **active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y**. This vaccine employs polysaccharide antigens from the bacterial capsule of each targeted serogroup conjugated to a protein carrier (such as diphtheria toxoid or CRM197), which enhances immunogenicity by stimulating a T cell–dependent immune response. It does not protect against serogroup B meningococci. Used worldwide and recommended for adolescents, high-risk individuals, travelers to endemic areas (e.g., for Hajj), and during outbreaks, it is highly efficacious and has a strong safety record, with rare but possible local reactions. Common brands include Menactra, Menveo, Menquadfi, and Nimenrix, developed by Sanofi, GSK (GlaxoSmithKline, now Pfizer), and Novartis (now GSK/Pfizer). The vaccine plays a central role in the prevention of bacterial meningitis and septicemia.
- Brand names
- MenactraMenveoMenquadfiNimenrix
- Other names
- MenACWY vaccinequadrivalent meningococcal conjugate vaccineMCV4MCV-4MCV 4
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal conjugate vaccine (serogroups A, C, W-135, and Y).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal conjugate vaccine (serogroups A, C, W-135, and Y).